Recent studies have indicated specificity of FGF21 for FGFR1-KLB in adipose tissue [11,12,13], and that the administration of rFGF21 to obese and diabetic patients does not stimulate tumor growth [10,49,50]. Here, FGFR1 is linked to neoplasm.